About Us
Our Founders
Jiawu Song, MD, Ph.D
CEO Dr. Song has worked in the field of Gastroenterology for more than 20 years. He has been recognized for contributions to the diagnosis, treatment and prevention of gastroenterology diseases.Ziyan Pessetto, Ph.D, HCLD (ABB)
CSO
Dr. Pessetto is a Board-Certified High Complexity Laboratory Director (HCLD) specializing in molecular diagnostics, clinical oncology and pharmacogenomics. Dr. Pessetto completed her doctorate in cancer research in 2011 at the University of Nebraska Medical Center. She performed her postdoctoral training from 2011-2014 at University of Kansas Medical Center, where she was a recognized expert in drug development and drug-repurposing translational research. In 2014, she was appointed Assistant Director of the Clinical Molecular Oncology Laboratory (University of Kansas Health System), where she was responsible for the management and integration of molecular testing. In 2018, she was appointed Clinical Associate Professor. In 2019 she served as the co-Director of the Biobanking and Biomarker Validation Core, within in the COBRE Kansas Institute for Precision Medicine. Dr. Pessetto is an accomplished and well-established molecular biologist with expertise in the field of clinical molecular testing and has achieved an international reputation as a well-respected expert within the field of precision medicine.
Andrew Godwin, Ph.D
Dr. Godwin is a leader in the field of translational research and precision medicine, and members of his research program continue to focus on various aspects of both basic and translational research. He is an NCI funded investigator (continuously since 1993) and a highly published (>470 manuscripts and scholarly review articles) scientist. In 2010, he joined KUMC as the Associate Director for Translational Research for the KU Cancer Center after 26 productive years at Fox Chase Cancer Center (FCCC). Godwin is internationally recognized for his molecular biology/genetic studies of cancers including, sarcoma, breast and ovarian, and his efforts to help bridge the gap between basic and clinical science in order to improve patient care. Sinochips Diagnostics was founded in early 2019 by Jiawu Song, MD, Ph.D with two co-founders Ziyan Pessetto, Ph.D, HCLD (ABB), and Andrew Godwin, Ph.D – who recognized clinicians were looking for comprehensive pharmacogenomic testing. Sinochips Diagnostics is located in Olathe, Kansas.
Our Founders
CEO
Dr. Song has worked in the field of Gastroenterology for more than 20 years. He has been recognized for contributions to the diagnosis, treatment and prevention of gastroenterology diseases.
Ziyan Pessetto, Ph.D, HCLD (ABB)
CSO
Dr. Pessetto is a Board-Certified High Complexity Laboratory Director (HCLD) specializing in molecular diagnostics, clinical oncology and pharmacogenomics. Dr. Pessetto completed her doctorate in cancer research in 2011 at the University of Nebraska Medical Center. She performed her postdoctoral training from 2011-2014 at University of Kansas Medical Center, where she was a recognized expert in drug development and drug-repurposing translational research. In 2014, she was appointed Assistant Director of the Clinical Molecular Oncology Laboratory (University of Kansas Health System), where she was responsible for the management and integration of molecular testing. In 2018, she was appointed Clinical Associate Professor. In 2019 she served as the co-Director of the Biobanking and Biomarker Validation Core, within in the COBRE Kansas Institute for Precision Medicine. Dr. Pessetto is an accomplished and well-established molecular biologist with expertise in the field of clinical molecular testing and has achieved an international reputation as a well-respected expert within the field of precision medicine.
Ziyan Pessetto, Ph.D, HCLD (ABB)
CSO
Dr. Pessetto is a Board-Certified High Complexity Laboratory Director (HCLD) specializing in molecular diagnostics, clinical oncology and pharmacogenomics. Dr. Pessetto completed her doctorate in cancer research in 2011 at the University of Nebraska Medical Center. She performed her postdoctoral training from 2011-2014 at University of Kansas Medical Center, where she was a recognized expert in drug development and drug-repurposing translational research. In 2014, she was appointed Assistant Director of the Clinical Molecular Oncology Laboratory (University of Kansas Health System), where she was responsible for the management and integration of molecular testing. In 2018, she was appointed Clinical Associate Professor. In 2019 she served as the co-Director of the Biobanking and Biomarker Validation Core, within in the COBRE Kansas Institute for Precision Medicine. Dr. Pessetto is an accomplished and well-established molecular biologist with expertise in the field of clinical molecular testing and has achieved an international reputation as a well-respected expert within the field of precision medicine.
Andrew Godwin, Ph.D
Dr. Godwin is a leader in the field of translational research and precision medicine, and members of his research program continue to focus on various aspects of both basic and translational research. He is an NCI funded investigator (continuously since 1993) and a highly published (>470 manuscripts and scholarly review articles) scientist. In 2010, he joined KUMC as the Associate Director for Translational Research for the KU Cancer Center after 26 productive years at Fox Chase Cancer Center (FCCC). Godwin is internationally recognized for his molecular biology/genetic studies of cancers including, sarcoma, breast and ovarian, and his efforts to help bridge the gap between basic and clinical science in order to improve patient care.
Andrew Godwin, Ph.D
Dr. Godwin is a leader in the field of translational research and precision medicine, and members of his research program continue to focus on various aspects of both basic and translational research. He is an NCI funded investigator (continuously since 1993) and a highly published (>470 manuscripts and scholarly review articles) scientist. In 2010, he joined KUMC as the Associate Director for Translational Research for the KU Cancer Center after 26 productive years at Fox Chase Cancer Center (FCCC). Godwin is internationally recognized for his molecular biology/genetic studies of cancers including, sarcoma, breast and ovarian, and his efforts to help bridge the gap between basic and clinical science in order to improve patient care.
Our Pharmacists
James A. Walker, PharmD, MSPGX
James A. Walker is a highly skilled Pharmacist with a distinguished background in Pharmacogenomics and Clinical Pharmacy. His expertise lies in utilizing genetic insights to optimize pharmacotherapy, ensuring personalized and effective patient care.
James holds a Doctor of Pharmacy (PharmD) from the University of Kansas School of Pharmacy and a Master of Science in Pharmacogenomics (MSPGX) from Manchester University.
As the Founder and CEO of PharmaGX Consultation LLC , James is at the forefront of pharmacogenomics. Through this venture, he provides in-depth consultations, leveraging genetic data to tailor medication regimens based on individual profiles. His commitment to advancing personalized medicine is evident in his collaborations with healthcare providers and laboratories to ensure the precise selection of genetic panels for optimal patient outcomes.
James is an active member of the Clinical Pharmacogenetics Implementation Consortium (CPIC), showcasing his commitment to advancing pharmacogenomic standards and practices. His involvement in CPIC reflects a dedication to staying at the forefront of precision medicine and contributing to the development of guidelines that shape the field.
Furthermore, James has enriched his professional experience through various pharmacy settings. These experiences allowed him to gain invaluable insights into diverse healthcare settings, including pediatrics, critical care, outpatient clinics, and government pharmacy. By being involved in these various settings, James has demonstrated his proactive approach to continuous learning and adapting to the dynamic landscape of pharmacy practice.
With a passion for leveraging cutting-edge pharmacogenomic insights and providing exemplary clinical pharmacy services, James stands as a leader in advancing patient-centric and personalized healthcare.
